Can a new drug delay Alzheimer's in people with a genetic mutation?

NCT ID NCT06384573

First seen Nov 12, 2025 · Last updated May 13, 2026 · Updated 20 times

Summary

This study tests the drug lecanemab in 40 people who have a genetic form of Alzheimer's disease. The goal is to see if removing amyloid plaques from the brain can delay the start of symptoms or slow the disease. Participants previously received another anti-amyloid drug and will now receive lecanemab to see if it can fully clear plaques and improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Indiana University School of Medicine

    Indianapolis, Indiana, 46202, United States

  • Neuroscience Research Australia

    Randwick, New South Wales, 2031, Australia

  • The National Hospital for Neurology and Neurosurgery

    London, Greater London, WC1B 3BG, United Kingdom

  • University of Alabama in Birmingham

    Birmingham, Alabama, 35294, United States

  • University of Washington

    Seattle, Washington, 98195, United States

  • Washington University in St. Louis

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.